Welcome to our dedicated page for CERENOME SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERENOME's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERENOME's regulatory disclosures and financial reporting.
Plus Therapeutics, Inc. Schedule 13G/A filed by S.H.N. Financial Investments Ltd. reports beneficial ownership of 1,500,000 shares of common stock, representing 1.51% of the class based on 99,264,526 shares outstanding. The amendment references a prior Schedule 13G filed March 18, 2025, which covered 1,209,754 shares purchased March 4, 2025, indicating the reporter increased its position to the 1.5 million share level.
The filer is S.H.N. Financial Investments Ltd., organized in Israel, with Nir Shamir identified as CEO of the reporting entity and noted as potentially deemed to beneficially own the reported shares, though he disclaims ownership for other purposes. The filing certifies the shares were not acquired to influence control of the issuer.
Plus Therapeutics reported that Nasdaq's Listing Qualifications Department found it did not meet the minimum stockholders' equity requirement after the company reported a stockholders' deficit of ($23,641,000) for the period ended March 31, 2025. The Staff initially determined to delist the company's securities, and the company timely requested a hearing.
A Nasdaq Hearings Panel granted continued listing subject to two conditions: demonstrate compliance with the $2.5 million equity requirement by August 14, 2025 through a public filing describing transactions and indicating post-transaction equity (optionally including a balance sheet not older than 60 days with pro forma adjustments), and have the closing bid price meet or exceed $1.00 per share for 10 consecutive business days by September 8, 2025.
Plus Therapeutics reported the results of its August 7, 2025 annual meeting. Of 60,490,101 shares outstanding at the June 18, 2025 record date, 29,973,272 shares were represented, constituting a quorum. All director nominees listed in the proxy were elected, with individual "for" votes generally in the range of 18.7 million to 18.94 million and 10,294,600 broker non-votes recorded for those director elections.
Stockholders approved several material proposals: authorization to potentially issue up to $50.0 million of common stock (plus up to $1.0 million as a commitment fee) to Lincoln Park Capital under the June 17, 2025 purchase agreement; discretionary authority for the board to effect a reverse stock split at any ratio between 1-for-2 and 1-for-250; an advisory approval of named executive officer compensation; and the fifth amendment and restatement of the 2020 Stock Incentive Plan.
Plus Therapeutics (PSTV) filed a registration statement to register up to 33,000,000 shares for resale by Lincoln Park Capital Fund under a purchase agreement that can provide up to $50.0 million of aggregate gross proceeds (an initial $25.0 million available amount with an automatic additional $25.0 million upon satisfaction of conditions). The company has received approximately $2.8 million to date and intends to issue 1,612,903 Initial Commitment Shares valued at $0.31 as part of the commitment fee. The filing shows 99,264,526 shares outstanding and a pro forma 132,264,526 if all registered shares are issued, and highlights potential dilution, dependence on Lincoln Park as a financing source, a disclosed Make-Whole Repayment obligation of approximately $17.3 million, and that any proceeds would be used for working capital, general corporate purposes and, if required, repayment obligations.
Schedule 13G/A (Amendment No. 1) filing for Plus Therapeutics, Inc. (NASDAQ: PSTV) discloses that The Hewlett Fund LP no longer holds any beneficial ownership in the company’s common stock.
Key facts:
- Date of event: 24 June 2025
- Reporting person: The Hewlett Fund LP (a New York limited partnership)
- Shares beneficially owned: 0.00
- Percent of class: 0%
- Voting & dispositive power: 0 shares sole or shared
- Reason for filing: Ownership has fallen to (or remains) 5 percent or less of outstanding common stock, triggering a final amendment under Rule 13d-2.
This amendment replaces an earlier Schedule 13G in which the same fund reported an ownership position exceeding the 5 % reporting threshold. By certifying zero shares, The Hewlett Fund LP confirms that it has fully exited its previously disclosed stake and no longer seeks to influence control of Plus Therapeutics. Apart from this ownership update, the filing contains no financial performance data, strategic commentary or transactional details.
The Securities and Exchange Commission has declared Plus Therapeutics' Form S-1 registration statement effective as of June 23, 2025, at 9:00 A.M. The registration statement was filed under File Number 333-288121.
A Form S-1 is a crucial SEC filing used for registering new securities offerings with the SEC. This effectiveness notice indicates that Plus Therapeutics has completed the registration process and received regulatory approval to proceed with their planned securities offering.
This development is significant for investors as it typically precedes:
- A new public offering of securities
- The ability to begin selling registered securities to the public
- Potential changes in the company's capital structure